Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1977 Apr 1;55(7):351-3.
doi: 10.1007/BF01488116.

[Behaviour of plasma renin activity during long-term treatment with propranolol (author's transl)]

[Article in German]

[Behaviour of plasma renin activity during long-term treatment with propranolol (author's transl)]

[Article in German]
H Witzgall et al. Klin Wochenschr. .

Abstract

17 patients (40 +/- 9 years) with essential hypertension were included in the study. A monotherapy of 120, 160 or 240 mg propranolol per day was administered orally according to the antihypertensive effect. Four weeks after treatment, blood pressure and heart rate showed a statistically significant decrease and remained unchanged over a period of six months. Plasma renin activity decreased significantly from 5.7 +/- 6.3 ng/ml/h at the beginning of the study to 1.8 +/- 1.3 ng/ml/h after 4 weeks. 5 months later however plasma renin activity increased again to 5.0 +/- 0.9 ng/ml/h. The difference was statistically significant. From 17 patients 7 (41%) had lower levels of plasma renin activity after 6 months treatment when compared with pretreatment values. In only 3 patients (18%) was plasma renin activity lower after 6 months than after four weeks. We conclude that the increase in plasma renin activity is a reactive mechanism to the reduced blood pressure under long-term conditions. The decrease of plasma renin activity in short-term treatment of essential hypertension is not a mechanism responsible for the antihypertensive effect of propranolol during long-term treatment.

PubMed Disclaimer

Similar articles

References

    1. Acta Med Scand. 1975 Jun;197(6):457-61 - PubMed
    1. Br J Clin Pharmacol. 1975 Apr;2(2):159-64 - PubMed
    1. J Clin Endocrinol Metab. 1972 Feb;34(2):386-94 - PubMed
    1. Klin Wochenschr. 1976 Aug 15;54(16):765-73 - PubMed
    1. Br Med J. 1974 Jan 12;1(5897):60-2 - PubMed

Publication types